The Food and Drug Administration (FDA) has approved updated labeling for Sublocade ® (buprenorphine extended-release) injection to include a rapid induction protocol and alternative injection sites.

Key Label Changes Include ... Risk of Serious Injection Site Reactions: Likelihood of may increase with inadvertent intramuscular or intradermal administration. Evaluate and treat as appropriate.

These FDA label changes can provide ... Risk of Serious Injection Site Reactions: Likelihood of may increase with inadvertent intramuscular or intradermal administration. Evaluate and treat ...

1,2 Alternative Injection Sites: SUBLOCADE can now be administered ... flexibility in treatment administration 2. These FDA label changes can provide important benefits for patients and healthcare ...

Competitive kinetic isotope effects can also be determined. The resultant data are expected to be useful in the construction of predictive models across several dimensions including reaction ...